EZH2 PROTACs Outperform Catalytic Inhibitors in Prostate Cancer by Targeting a Methylation-Independent Function of PRC2

The authors designed and developed a series of VHL-based proteolysis-targeting chimera (PROTAC) degraders of EZH2 using EPZ-6438 as a ligand and identified PROTAC-6272 as a lead compound.